title: Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
abstract: (90)Y radioembolization (selective internal radiation therapy [SIRT]) is a valuable therapeutic option for unresectable hepatic metastases arising from primary colorectal cancer. The present study evaluated the prognostic value of (18)F-FDG PET/CT metabolic parameters for predicting survival after SIRT.
  
  
  METHODS
  Eighty patients with hepatic metastases of colorectal cancer were treated with SIRT. (18)F-FDG PET/CT was performed at baseline and 3 mo after the treatment. Metabolic volume, total lesion glycolysis, and maximum and peak standardized uptake value (SUV(max) and SUV(peak), respectively) according to PET Response Criteria in Solid Tumors (PERCIST 1.0) were obtained from 3 liver lesions in each patient, and the corresponding percentage changes from baseline to follow-up were calculated. Tumor response was defined as more than a 30% decrease in these parameters. Furthermore, response was evaluated in accordance with Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Toxicity events and survival were recorded.
  
  
  RESULTS
  Overall median survival after SIRT was 60 wk. Responders who had a change in metabolic volume or total lesion glycolysis had significantly longer survival (92 vs. 49 wk [P = 0.006] and 91 vs. 48 wk [P = 0.025], respectively). However, neither RECIST 1.1 criteria nor changes in SUV(peak) or SUV(max) after treatment predicted outcome (P = 0.086 for RECIST; P = 0.310 for change in SUV(peak); P = 0.155 for change in SUV(max)).
  
  
  CONCLUSIONS
  Changes in metabolic volume and total lesion glycolytic rate as measured by (18)F-FDG PET predicted survival in patients with hepatic metastases from colorectal cancer, whereas changes in SUV(peak) or SUV(max) and RECIST 1.1 criteria did not predict survival.
authors.affiliation: Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany. wolfgang.fendler@med.uni-muenchen.de
authors.forename: Wolfgang Peter
authors.initials: WP
authors.lastname: Fendler
authors.forename: Donfack Beauclair
authors.initials: DB
authors.lastname: Philippe Tiega
authors.forename: Harun
authors.initials: H
authors.lastname: Ilhan
authors.forename: Philipp M
authors.initials: PM
authors.lastname: Paprottka
authors.forename: Volker
authors.initials: V
authors.lastname: Heinemann
authors.forename: Tobias F
authors.initials: TF
authors.lastname: Jakobs
authors.forename: Peter
authors.initials: P
authors.lastname: Bartenstein
authors.forename: Marcus
authors.initials: M
authors.lastname: Hacker
authors.forename: Alexander Robert
authors.initials: AR
authors.lastname: Haug
mesh_terms: D015179:Colorectal Neoplasms / Q000473:pathology*; D004621:Embolization, Therapeutic / Q000009:adverse effects; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy* / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D011379:Prognosis; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D015021:Yttrium Radioisotopes; D019788:Fluorodeoxyglucose F18
keywords: 18F-FDG PET; 90Y microspheres; SIRT; hepatic metastases; radioembolization